Lawmakers should take their earliest opportunity to give small-molecule drugs the same 13-year exemption as biologics, and allow multi-use orphan drugs to keep their exemption as well.
Last week, a federal court in Ohio denied a preliminary injunction motion by four Chambers of Commerce in their lawsuit against the Medicare Drug Price Negotiation Program.